Skip to content

Intra-Prostatic Epinephrine Injection in Bipolar Transurethral Resection of Large Prostate: Exploring Its Role in Optimizing Surgical Outcomes

Intra-Prostatic Epinephrine Injection in Bipolar Transurethral Resection of Large Prostate: Exploring Its Role in Optimizing Surgical Outcomes

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07733167
Enrollment
80
Registered
2026-07-29
Start date
2025-03-20
Completion date
2026-10-20
Last updated
2026-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intra-Prostatic Epinephrine Injection in Bipolar Transurethral Resection of Large Prostate

Brief summary

Intra-Prostatic Epinephrine injection in Bipolar Transurethral resection of large prostate: Exploring Its Role in Optimizing Surgical Outcomes

Interventions

DEVICETURP

Intra-Prostatic Epinephrine injection in Bipolar Transurethral resection of large prostate

DRUGEpinephrine

Intra-Prostatic epinephrine injection in Bipolar Transurethral resection of large prostate

Sponsors

Benha University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Indication for Prostate Surgery or Procedure - Patients undergoing transurethral resection of the prostate (TURP) * Prostate from 80 to 100 gm * Failed medical therapy

Exclusion criteria

* Uncontrolled Hypertension - Patients with significantly high blood pressure despite medication therapy. * Unstable angina, recent myocardial infarction, arrhythmias, or severe heart failure. * Significant Coagulopathy - Patients with bleeding disorders or on anticoagulants where excessive vasoconstriction may lead to tissue necrosis or inadequate perfusion * Hyperthyroidism, Pheochromocytoma or Endocrine Disorders - Patients with catecholamine-secreting tumors or other conditions that can lead to excessive sympathetic stimulation. * Treatment in the last 3 months with 5-alpha reductase inhibitors. * Genitourinary cancer, urinary tract lithiasis, and urological surgery within the last 3 months

Design outcomes

Primary

MeasureTime frameDescription
Intraoperative blood loss , need of blood transfusion24h post operativeassessment of Blood Loss (Irrigation Fluid Hb Concentration): Bladder irrigation will be maintained for 24 hours post operatively, with fluid collections made at three intervals: Immediately postsurgery (V1), 6 hours postoperation (V2), and 24 hours postoperation (V3). The total volume collected will be measured, and 5000U of heparin will be added to each irrigation fluid container to prevent coagulation. After thorough mixing, 5-mL samples will be extracted and analyzed using cyanide met hemoglobin spectrophotometry at 540 nm to determine the Hb concentration. Blood loss will be estimated using specific formulas: (1) Hb concentration in irrigation fluid (g/L) = absorbance of fluid × 367.7; (2) Bleeding volume (mL) = (Hb concentration in irrigation fluid (g/L) × rinse volume (mL)) / preoperative Hb concentration(g/L).

Secondary

MeasureTime frameDescription
Prostate volume , post voiding residual urine3 monthsprostate volume \& post voiding residual urine will be measured by Transrectal ultrasound

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026